63 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Johnston SJ, Syed BM, Parks RM, Monteiro CJ, Caruso JA, Green AR, Ellis IO, Hunt KK, Karakas C, Keyomarsi K, Cheung KL. Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. Cancers. 12. PMID 32197318 DOI: 10.3390/cancers12030712  0.4
2020 Mull BB, Livingston JA, Patel N, Bui T, Hunt KK, Keyomarsi K. Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. British Journal of Cancer. PMID 31942030 DOI: 10.1038/s41416-019-0707-z  0.4
2019 Karakas C, Francis AM, Ha MJ, Wingate HF, Meena RA, Yi M, Rasaputra KS, Barrera AMG, Arun B, Do KA, Sahin A, Keyomarsi K, Hunt KK. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Annals of Surgery. PMID 31436549 DOI: 10.1097/SLA.0000000000003551  0.4
2019 Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JP, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, ... ... Keyomarsi K, et al. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30867218 DOI: 10.1158/1078-0432.CCR-18-3274  0.4
2018 Caruso JA, Duong MT, Carey JPW, Hunt KK, Keyomarsi K. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Research. PMID 30194068 DOI: 10.1158/0008-5472.CAN-18-1235  0.4
2018 Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JP, Bui T, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, ... ... Keyomarsi K, et al. Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30181387 DOI: 10.1158/1078-0432.CCR-18-1446  0.4
2017 Carey JP, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K. Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer. Cancer Research. PMID 29180466 DOI: 10.1158/0008-5472.CAN-17-1494  0.4
2017 Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, ... ... Keyomarsi K, et al. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nature Communications. 8: 15916. PMID 28653662 DOI: 10.1038/ncomms15916  0.4
2017 Francis AM, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KK. CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest. Molecular Cancer Therapeutics. PMID 28619757 DOI: 10.1158/1535-7163.MCT-17-0040  0.4
2017 Alexander A, Karakas C, Chen X, Carey JP, Yi M, Bondy M, Thompson P, Cheung KL, Ellis IO, Gong Y, Krishnamurthy S, Alvarez RH, Ueno NT, Hunt KK, Keyomarsi K. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget. PMID 28107181 DOI: 10.18632/oncotarget.14689  0.4
2016 Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin A, Adjapong O, Hortobogyi GN, Bondy ML, Thompson PA, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, ... Keyomarsi K, et al. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27881578 DOI: 10.1158/1078-0432.CCR-16-2217  0.4
2016 Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, Bui TN, Warner S, Heymach JV, Hunt KK, Wang J, Byers LA, Keyomarsi K. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research : McR. PMID 27671334 DOI: 10.1158/1541-7786.MCR-16-0157  0.4
2016 Karakas C, Biernacka A, Bui T, Sahin A, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K. Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. The American Journal of Pathology. PMID 27182644 DOI: 10.1016/j.ajpath.2016.02.024  0.56
2016 JavanMoghadam S, Zhang W, Hunt KK, Keyomarsi K. Estrogen Receptor Alpha is Cell Cycle-Regulated and Regulates the Cell Cycle in a Ligand-Dependent Fashion. Cell Cycle (Georgetown, Tex.). 0. PMID 27049344 DOI: 10.1080/15384101.2016.1166327  0.4
2016 Lucenay KS, Doostan I, Karakas C, Bui T, Ding Z, Mills GB, Hunt KK, Keyomarsi K. Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells. Cancer Research. PMID 26928812 DOI: 10.1158/0008-5472.CAN-15-1646  0.4
2016 Jabbour-Leung NA, Chen X, Bui T, Jiang Y, Yang D, Vijayaraghavan S, McArthur MJ, Hunt KK, Keyomarsi K. Sequential combination therapy of CDK inhibition and doxorubicin is synthetically lethal in p53-mutant triple-negative breast cancer. Molecular Cancer Therapeutics. PMID 26826118 DOI: 10.1158/1535-7163.MCT-15-0519  0.32
2015 Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Research : Bcr. 17: 87. PMID 26108797 DOI: 10.1186/s13058-015-0572-5  0.4
2015 Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Investigational New Drugs. 33: 890-4. PMID 25947565 DOI: 10.1007/s10637-015-0244-4  0.32
2015 Pickering CR, Bast RC, Keyomarsi K. How will we recruit, train, and retain physicians and scientists to conduct translational cancer research? Cancer. 121: 806-16. PMID 25355050 DOI: 10.1002/cncr.29033  0.32
2014 Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Research : Bcr. 16: 3417. PMID 25551582 DOI: 10.1186/s13058-014-0497-4  0.32
2014 Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, ... ... Keyomarsi K, et al. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications. 5: 3459. PMID 24619206 DOI: 10.1038/ncomms4459  0.32
2013 Duong MT, Akli S, Macalou S, Biernacka A, Debeb BG, Yi M, Hunt KK, Keyomarsi K. Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells. Cancer Research. 73: 5556-68. PMID 23955388 DOI: 10.1158/0008-5472.CAN-13-0013  0.32
2013 Murray MM, Bui T, Smith M, Bagheri-Yarmand R, Wingate H, Hunt KK, Keyomarsi K. Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis. 34: 2244-52. PMID 23722650 DOI: 10.1093/carcin/bgt186  0.56
2013 Dutta P, Bui T, Bauckman KA, Keyomarsi K, Mills GB, Nanjundan M. EVI1 splice variants modulate functional responses in ovarian cancer cells. Molecular Oncology. 7: 647-68. PMID 23517670 DOI: 10.1016/j.molonc.2013.02.008  0.32
2013 Hunt KK, Wingate H, Yokota T, Liu Y, Mills GB, Zhang F, Fang B, Su CH, Zhang M, Yi M, Keyomarsi K. Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Research : Bcr. 15: R3. PMID 23320734 DOI: 10.1186/bcr3374  0.56
2012 Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. Plos Genetics. 8: e1002538. PMID 22479189 DOI: 10.1371/journal.pgen.1002538  0.56
2012 Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K. Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle (Georgetown, Tex.). 11: 1468-76. PMID 22441703 DOI: 10.4161/cc.19882  0.56
2012 Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, Galons H, Joseph B, Meijer L, Hunt KK, Keyomarsi K. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Research and Treatment. 132: 575-88. PMID 21695458 DOI: 10.1007/s10549-011-1638-4  0.32
2011 Valero V, Wingate H, Chada S, Liu Y, Palalon F, Mills G, Keyomarsi K, Hunt KK. MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. Cancer Gene Therapy. 18: 510-9. PMID 21546925 DOI: 10.1038/cgt.2011.20  0.32
2011 Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Research. 71: 3377-86. PMID 21385896 DOI: 10.1158/0008-5472.CAN-10-4086  0.32
2011 Keyomarsi K, Efuet ET, Bui TN. Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells Cell Biology and Toxicology. 27: 123-131. PMID 20853140 DOI: 10.1007/s10565-010-9175-1  0.32
2010 Caruso JA, Hunt KK, Keyomarsi K. The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer. Cancer Research. 70: 7125-36. PMID 20823156 DOI: 10.1158/0008-5472.CAN-10-1547  0.32
2010 Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Research. 70: 5074-84. PMID 20530685 DOI: 10.1158/0008-5472.CAN-09-4094  0.4
2010 Bagheri-Yarmand R, Nanos-Webb A, Biernacka A, Bui T, Keyomarsi K. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. Cancer Research. 70: 5085-95. PMID 20530684 DOI: 10.1158/0008-5472.CAN-09-4095  0.4
2010 Sun B, Wingate H, Swisher SG, Keyomarsi K, Hunt KK. Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. Cell Cycle (Georgetown, Tex.). 9: 1122-30. PMID 20237430 DOI: 10.4161/cc.9.6.10990  0.56
2010 Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1179-90. PMID 20145171 DOI: 10.1158/1078-0432.CCR-09-1787  0.56
2009 Fearmonti RM, Keyomarsi K, Hunt KK. Biomarkers in neoadjuvant trials. Cancer Treatment and Research. 147: 1-36. PMID 21461824 DOI: 10.1007/978-0-387-09463-2_8  0.4
2009 Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, ... ... Keyomarsi K, et al. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. Plos Medicine. 6: e1000068. PMID 19536326 DOI: 10.1371/journal.pmed.1000068  0.32
2009 Delk NA, Hunt KK, Keyomarsi K. Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Research. 69: 2817-25. PMID 19318554 DOI: 10.1158/0008-5472.CAN-08-4182  0.32
2009 Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, Tucker SL, Van Pelt C, Meijer L, Hunt K, Keyomarsi K. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle (Georgetown, Tex.). 8: 1062-8. PMID 19305161  0.32
2009 Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Research and Treatment. 115: 651-9. PMID 19107593 DOI: 10.1007/s10549-008-0266-0  0.32
2008 Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Research. 68: 7966-74. PMID 18829554 DOI: 10.1158/0008-5472.CAN-08-1333  0.4
2007 Yokota T, Bui T, Liu Y, Yi M, Hunt KK, Keyomarsi K. Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. Cancer Research. 67: 11272-83. PMID 18056453 DOI: 10.1158/0008-5472.CAN-07-2322  0.4
2007 von Holzen U, Pataer A, Raju U, Bocangel D, Vorburger SA, Liu Y, Lu X, Roth JA, Aggarwal BB, Barber GN, Keyomarsi K, Hunt KK, Swisher SG. The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6032-9. PMID 17947465 DOI: 10.1158/1078-0432.CCR-06-2932  0.32
2007 Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4800-6. PMID 17699858 DOI: 10.1158/1078-0432.CCR-07-0142  0.56
2007 Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Research. 67: 7212-22. PMID 17671189 DOI: 10.1158/0008-5472.CAN-07-0599  0.32
2006 Barton MC, Akli S, Keyomarsi K. Deregulation of cyclin E meets dysfunction in p53: Closing the escape hatch on breast cancer Journal of Cellular Physiology. 209: 686-694. PMID 17001684 DOI: 10.1002/jcp.20818  0.32
2006 Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle (Georgetown, Tex.). 5: 1654-61. PMID 16861913  0.56
2005 Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 102: 12519-24. PMID 16116079 DOI: 10.1073/pnas.0505641102  0.32
2005 Hunt KK, Keyomarsi K. Cyclin E as a prognostic and predictive marker in breast cancer. Seminars in Cancer Biology. 15: 319-26. PMID 16043362 DOI: 10.1016/j.semcancer.2005.04.007  0.4
2005 Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. The Journal of Biological Chemistry. 280: 15148-57. PMID 15708847 DOI: 10.1074/jbc.M409789200  0.56
2005 Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, Reed JA, Timchenko N, van den Oord JJ, Bar-Eli M, Keyomarsi K, Medrano EE. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Research. 65: 692-7. PMID 15705861  0.32
2004 Akli S, Keyomarsi K. Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Research : Bcr. 6: 188-91. PMID 15318923 DOI: 10.1186/bcr905  0.56
2004 Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 59: 928-42. PMID 15234026 DOI: 10.1016/j.ijrobp.2004.03.005  0.32
2004 Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Research. 64: 3198-208. PMID 15126360 DOI: 10.1158/0008-5472.CAN-03-3672  0.32
2004 Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene. 23: 2648-57. PMID 15007381 DOI: 10.1038/sj.onc.1207408  0.56
2003 Keyomarsi K, Pardee AB. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Progress in Cell Cycle Research. 5: 527-32. PMID 14593747  0.32
2003 Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biology & Therapy. 2: S38-47. PMID 14508079  0.56
2003 Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle (Georgetown, Tex.). 2: 461-6. PMID 12963845  0.56
2003 Keyomarsi K, Tucker SL, Bedrosian I. Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nature Medicine. 9: 152. PMID 12563321 DOI: 10.1038/nm0203-152  0.56
2002 Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. The New England Journal of Medicine. 347: 1566-75. PMID 12432043 DOI: 10.1056/NEJMoa021153  0.56
2002 Blagosklonny MV, Campisi J, Keyomarsi K, Medrano EE. No restriction points in life and science. Cell Cycle (Georgetown, Tex.). 1: 100-2. PMID 12429915  0.32
1992 Pardee AB, Keyomarsi K. Modification of cell proliferation with inhibitors Current Opinion in Cell Biology. 4: 186-191. PMID 1376129 DOI: 10.1016/0955-0674(92)90031-7  0.32
Show low-probability matches.